The mission to improve
patient care
diagnostics
patient outcomes
Prostate cancer will affect 1 in 7 men. 1 The standards for screening and biopsy blindly sample the prostate without knowing where the cancer is, if any. We’re here to set a new standard of care with MRI-targeted fusion biopsies.
Focal Healthcare is a world-class medical device company dedicated to improving the physician and patient experience from prostate cancer diagnosis to treatment.
Meet the Fusion Bx
The Fusion Bx’s semi-robotic arm allows the probe to be maneuvered effortlessly, while maintaining consistent pressure on the prostate. With a freehand-like motion and minimal prostate deformation, the Fusion Bx enables you to accurately locate and target suspicious regions of interest.
A few guiding principles
Good design starts with form and function. Great design embodies the principles upon which it is built. Informed by our end users, our products are designed around three key pillars:
Accuracy
Reliably targets lesions using MRI-ultrasound fusion
Compared to ultrasound imaging, MRI can be considered the “Gold Standard” for detecting lesions. MRI-targeted biopsies with Fusion Bx addresses potential sources of inaccuracy during biopsy procedures by targeting 3 key areas: prostate deformation, patient motion and registration.
Efficiency
Simplified workflow minimizes training and procedural times
Innovative technology doesn’t need to be complicated. Driven by end users, our 4-step guided workflow and semi-robotic arm eases the procedure for both physicians and patients.
Accessibility
Cost effective and easy to use fusion biopsy solution
Through rigorous testing and a fine attention to detail, we’ve developed a quality cost effective solution for fusion biopsies. Thoughtful engineering, multi-probe compatibility and accommodating customer service makes our system accurate, efficient and accessible to everyone.
Fusion 101
Fusion biopsy technology combines previously taken MRIs with live ultrasound to improve the visibility of suspicious lesions in the prostate. This allows physicians to take fewer cores because lesions can now be targeted. Get to know more about fusion and the Fusion Bx.
Let us tell you more
Email us for more information and we’ll start the conversation.
Distributor Series: Top Geal Co., Ltd.
- February 7, 2023
Quantib® Prostate Now Integrates with Focal Healthcare’s Fusion Bx
- January 30, 2023
Distributor Series: Exodus Scientific
- January 13, 2023
1 Statistics – Prostate Cancer Canada. (n.d.). Retrieved from prostatecancer.ca
2 Cookson, M. S., MD, & Stratton, K. L., MD. (2018, April 10). Point: Is MRI fusion biopsy the new gold standard for diagnosis?Urology Times. Retrieved from urologytimes.com